Innoviva (NASDAQ:INVA) Releases Earnings Results

Innoviva (NASDAQ:INVA) posted its quarterly earnings data on Wednesday. The biotechnology company reported $0.57 EPS for the quarter, Zacks reports. Innoviva had a return on equity of 20.84% and a net margin of 18.31%. The company had revenue of $91.81 million for the quarter.

Innoviva Price Performance

Shares of NASDAQ INVA traded up $0.09 during trading on Friday, hitting $17.64. The company had a trading volume of 85,925 shares, compared to its average volume of 525,970. The business’s 50-day moving average is $18.03 and its 200 day moving average is $18.85. The company has a market cap of $1.10 billion, a P/E ratio of 25.60 and a beta of 0.55. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.64 and a current ratio of 1.79. Innoviva has a 52 week low of $14.32 and a 52 week high of $21.28.

Analysts Set New Price Targets

Separately, StockNews.com cut shares of Innoviva from a “buy” rating to a “hold” rating in a research report on Saturday, February 22nd.

Innoviva Company Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.